At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 322 enrolled
Drug / intervention
CBP-201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
In Brief
A Phase 2 clinical trial evaluating CBP-201 and Placebo for Moderate to Severe Persistent Asthma. Completed, enrolled 322 participants across 76 sites in 5 countries.
Detailed Summary
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Persistent Asthma
CountriesChina, Hungary, Poland, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2021
Enrollment StartMay 2021
Primary CompletionAug 2023
Study CompletionSep 2023
TodayJul 2026
First PostedFeb 26, 2021
Enrollment StartMay 11, 2021
Primary CompletionAug 5, 2023
Study CompletionSep 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.4 years ago
Interventions
CBP-201drug
CBP-201 subcutaneous (SC) injection.
Placebodrug
Placebo subcutaneous (SC) injection.